NEW YORK (GenomeWeb) – Sygnis announced that it plans to raise up to €6.6 million ($8.1 million) through a private stock placement to help fund its planned acquisition of Australian reagent maker TGR Biosciences.

Sygnis said it will offer up to approximately 4.7 million newly issued shares to European institutional investors at a price of €1.40 per share. Proceeds from the offering will be used to acquire TGR, which Sygnis has agreed to buy for €10.4 million in cash and potentially convertible bonds.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.